Prostaglandin ethanolamides attenuate damage in a human explant colitis model

Prostaglandins and Other Lipid Mediators

Volumn 100-101, Issue 1, 2013, Pages 22-29

  Nicotra, Lauren L ^a   Vu, Megan ^a   Harvey, Benjamin S ^a   Smid, Scott D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Anandamide; Bimatoprost; Colitis; Prostamides

Indexed keywords

ANANDAMIDE; BIMATOPROST; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; PROSTAGLANDIN F2 ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL COUNT; COLITIS; COLON MUCOSA; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; SCORING SYSTEM; SIGNAL TRANSDUCTION; TISSUE INJURY;

ADULT; AMIDES; ARACHIDONIC ACIDS; CLOPROSTENOL; COLITIS; COLON, SIGMOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROST; DINOPROSTONE; ENDOCANNABINOIDS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; OXAZOLES; POLYUNSATURATED ALKAMIDES; RECEPTORS, PROSTAGLANDIN; SULFONAMIDES; TISSUE CULTURE TECHNIQUES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84874977115     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2013.01.003     Document Type: Article

References (33)

1. A.A. Izzo, and K.A. Sharkey Cannabinoids and the gut: new developments and emerging concepts Pharmacol Ther 126 1 2010 21 38
2. F. Massa, G. Marsicano, and H. Hermann The endogenous cannabinoid system protects against colonic inflammation J Clin Invest 113 8 2004 1202 1209
3. E.S. Kimball, C.R. Schneider, N.H. Wallace, and P.J. Hornby Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium Am J Physiol Gastrointest Liver Physiol 291 2 2006 G364 G371
4. R. Mathison, W. Ho, Q.J. Pittman, J.S. Davison, and K.A. Sharkey Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats Br J Pharmacol 142 8 2004 1247 1254
5. H.B. Bradshaw, and J.M. Walker The expanding field of cannabimimetic and related lipid mediators Br J Pharmacol 144 4 2005 459 465
6. F. Correa, F. Docagne, D. Clemente, L. Mestre, C. Becker, and C. Guaza Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2) Biochem J 409 3 2008 761 770
7. A. Di Sabatino, N. Battista, and P. Biancheri The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease Mucosal Immunol 4 5 2011 574 583
8. K.R. Kozak, B.C. Crews, and J.D. Morrow Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides J Biol Chem 277 47 2002 44877 44885
9. I. Matias, J. Chen, and L. De Petrocellis Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism J Pharmacol Exp Ther 309 2 2004 745 757
10. D.F. Woodward, A.H. Krauss, and J.W. Wang Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin- ethanolamides) in the feline iris Br J Pharmacol 150 3 2007 342 352
11. G. D'Argenio, M. Valenti, G. Scaglione, V. Cosenza, I. Sorrentini, and V. Di Marzo Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation FASEB J 20 3 2006 568 570
12. L. Marquez, J. Suarez, M. Iglesias, F.J. Bermudez-Silva, F. Rodriguez de Fonseca, and M. Andreu Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue PLoS One 4 9 2009 e6893
13. P.J. Roberts, K. Morgan, R. Miller, J.O. Hunter, and S.J. Middleton Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease Gut 48 4 2001 468 472
14. S.D. Smid, and K.M. Svensson Inhibition of cyclooxygenase-2 and EP1 receptor antagonism reduces human colonic longitudinal muscle contractility in vitro Prostaglandins Other Lipid Mediat 88 3-4 2009 117 121
15. M. Kruschewski, T. Foitzik, A. Perez-Cantó, A. Hũbotter, and H.J. Buhr Changes of colonic mucosal microcirculation and histology in two colitis models: an experimental study using intravital microscopy and a new histological scoring system Dig Dis Sci 46 11 2001 2336 2343
16. M.K. Ramarao, E.A. Murphy, and M.W. Shen A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening Anal Biochem 343 1 2005 143 151
17. K.A. Papadakis, J. Prehn, and D. Zhu Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa Inflamm Bowel Dis 10 6 2004 778 788
18. Watanabe, M. Yamazaki, M. Kanai, and T. Mucosal T cells as a target for treatment of IBD J Gastroenterol 38 Suppl. 15 2003 48 50
19. B. Funke, F. Autschbach, and S. Kim Functional characterisation of decoy receptor 3 in Crohn's disease Gut 58 4 2009 483 491
20. N.A. Sharif, C.R. Kelly, and G.W. Williams Bimatoprost (Lumigan((R))) is an agonist at the cloned human ocular FP prostaglandin receptor: real-time FLIPR-based intracellular Ca(2+) mobilization studies Prostaglandins Leukot Essent Fatty Acids 68 1 2003 27 33
21. L. Gatta, F. Piscitelli, and C. Giordano Discovery of prostamide f(2alpha) and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability PLoS One 7 2 2012 e31111
22. J. Chen, R.T. Lu, and R. Lai Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors Curr Eye Res 34 3 2009 184 195
23. Y.H. Ooi, D.J. Oh, and D.J. Rhee Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells Invest Ophthalmol Vis Sci 50 11 2009 5259 5265
24. C. Medina, and M.W. Radomski Role of matrix metalloproteinases in intestinal inflammation J Pharmacol Exp Ther 318 3 2006 933 938
25. Y. Liang, D.F. Woodward, and V.M. Guzman Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes Br J Pharmacol 154 5 2008 1079 1093
26. E. Furrie, S. Macfarlane, G. Thomson, and G.T. Macfarlane Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria Immunology 115 4 2005 565 574
27. L.T. Olsen Hult, C.R. Kleiveland, K. Fosnes, M. Jacobsen, and T. Lea EP receptor expression in human intestinal epithelium and localization relative to the stem cell zone of the crypts PLoS One 6 10 2011 e26816
28. G.L. Jiang, W.B. Im, Y. Donde, and L.A. Wheeler Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment J Pharmacol Exp Ther 335 3 2010 546 552
29. D.F. Woodward, R.L. Jones, and S. Narumiya International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress Pharmacol Rev 63 3 2011 471 538
30. C.E. Rockwell, P. Raman, B.L. Kaplan, and N.E. Kaminski A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells Biochem Pharmacol 76 3 2008 353 361
31. M. Hori, M. Kita, and S. Torihashi Upregulation of iNOS by COX-2 in muscularis resident macrophage of rat intestine stimulated with LPS Am J Physiol Gastrointest Liver Physiol 280 5 2001 G930 G938
32. I.I. Singer, D.W. Kawka, S. Schloemann, T. Tessner, T. Riehl, and W.F. Stenson Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease Gastroenterology 115 2 1998 297 306
33. M. Storr, D. Emmerdinger, and J. Diegelmann The role of fatty acid hydrolase gene variants in inflammatory bowel disease Aliment Pharmacol Ther 29 5 2009 542 551